PL330361A1 - Leptin fragments (ob proteins) - Google Patents

Leptin fragments (ob proteins)

Info

Publication number
PL330361A1
PL330361A1 PL97330361A PL33036197A PL330361A1 PL 330361 A1 PL330361 A1 PL 330361A1 PL 97330361 A PL97330361 A PL 97330361A PL 33036197 A PL33036197 A PL 33036197A PL 330361 A1 PL330361 A1 PL 330361A1
Authority
PL
Poland
Prior art keywords
proteins
leptin fragments
leptin
fragments
Prior art date
Application number
PL97330361A
Other languages
English (en)
Inventor
Kamal A Al-Barazanji
Jonathan Robert Sanders Arch
Patrick Camilleri
William Arthur Neville
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9611775.9A external-priority patent/GB9611775D0/en
Priority claimed from GBGB9618540.0A external-priority patent/GB9618540D0/en
Priority claimed from GBGB9703493.8A external-priority patent/GB9703493D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of PL330361A1 publication Critical patent/PL330361A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL97330361A 1996-06-06 1997-06-04 Leptin fragments (ob proteins) PL330361A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9611775.9A GB9611775D0 (en) 1996-06-06 1996-06-06 Novel compounds
GBGB9618540.0A GB9618540D0 (en) 1996-09-05 1996-09-05 Novel compounds
GBGB9703493.8A GB9703493D0 (en) 1997-02-20 1997-02-20 Novel compounds

Publications (1)

Publication Number Publication Date
PL330361A1 true PL330361A1 (en) 1999-05-10

Family

ID=27268305

Family Applications (1)

Application Number Title Priority Date Filing Date
PL97330361A PL330361A1 (en) 1996-06-06 1997-06-04 Leptin fragments (ob proteins)

Country Status (15)

Country Link
EP (1) EP0912609A2 (fr)
JP (1) JP2000512137A (fr)
KR (1) KR20000016402A (fr)
CN (1) CN1221426A (fr)
AR (1) AR008765A1 (fr)
AU (1) AU3337297A (fr)
BR (1) BR9709529A (fr)
CA (1) CA2257240A1 (fr)
CZ (1) CZ397898A3 (fr)
IL (1) IL127153A0 (fr)
NO (1) NO985683L (fr)
NZ (1) NZ332879A (fr)
PL (1) PL330361A1 (fr)
TR (1) TR199802534T2 (fr)
WO (1) WO1997046585A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2335107C (fr) 1998-07-28 2010-01-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Induction de genes a mediation par la leptine
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
WO2001021647A2 (fr) * 1999-09-22 2001-03-29 Genset Procedes de criblage de composes qui modulent l'interaction de la lsr-leptine et utilisations de ces composes dans la prevention et le traitement des maladies liees a l'obesite
AU8178401A (en) 2000-05-22 2001-12-03 Vlaams Interuniv Inst Biotech Receptor-based interaction trap
WO2003034996A2 (fr) 2001-10-22 2003-05-01 Amgen, Inc. Utilisation de leptine pour traiter la lipoatrophie humaine et procede pour determiner une predisposition a ce traitement
CA2535021A1 (fr) 2003-09-08 2005-03-17 Applied Research Systems Ars Holding N.V. Utilisation de l'insp035 dans le traitement de maladies fibreuses
EP2417980A1 (fr) 2004-02-11 2012-02-15 Amylin Pharmaceuticals Inc. Polypeptides hybrides présentant des propriétés pouvant être choisies
EP1812038A1 (fr) 2004-11-18 2007-08-01 VIB vzw Domaine de fibronectine iii servant d'antagonistes de recepteurs de la leptine
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
CA2597649A1 (fr) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Analogues de gip et polypeptides hybrides de gip aux proprietes selectionnables
US7629315B2 (en) 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
ES2319048B1 (es) * 2007-06-20 2010-02-10 Universitat De Les Illes Balears Uso de leptina en el tratamiento de alteraciones en los habitos alimentarios.
US8889622B2 (en) 2007-07-25 2014-11-18 Washington University Methods of inhibiting seizure in a subject
GB2451858A (en) * 2007-08-15 2009-02-18 Sergiy Konovchuk Methods of reducing body fat and treating obesity
CA2707555A1 (fr) 2007-12-05 2009-06-11 Astrazeneca Ab Piperazines comme agents anti-obesite
ATE546441T1 (de) 2007-12-05 2012-03-15 Astrazeneca Ab Piperazinderivate und ihre verwendung als modulatoren des leptinrezeptors
JP2011522007A (ja) * 2008-06-04 2011-07-28 アストラゼネカ アクチボラグ レプチン受容体修飾因子模倣剤としての新しいピリジン誘導体
CA2725949A1 (fr) * 2008-06-04 2009-12-10 Astrazeneca Ab Nouveaux composes v
WO2010118384A2 (fr) 2009-04-10 2010-10-14 Amylin Pharmaceuticals, Inc. Composés agonistes de l'amyline pour mammifères ayant une carence en oestrogènes
EP2569326B1 (fr) * 2010-05-11 2016-08-10 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibiteur peptidique de la signalisation de l'interleukine-10 ou de l'activation de stat-3
WO2012050925A2 (fr) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Inc. Leptines hautement solubles
CN104829707B (zh) * 2015-05-06 2017-12-19 广东省生物资源应用研究所 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用
CN110183530A (zh) * 2019-06-21 2019-08-30 深圳市亚辉龙生物科技股份有限公司 瘦素免疫原、杂交瘤细胞、单克隆抗体、多克隆抗体及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO1996023514A1 (fr) * 1995-01-31 1996-08-08 Eli Lilly And Company Proteines anti-obesite
US5552523A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
WO1996023815A1 (fr) * 1995-01-31 1996-08-08 Eli Lilly And Company Anticorps contre les produits du gene ob
WO1996031526A1 (fr) * 1995-04-06 1996-10-10 Amylin Pharmaceuticals, Inc. Agents antiobesite
GB9509164D0 (en) * 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
EP0912609A2 (fr) 1999-05-06
AR008765A1 (es) 2000-02-23
IL127153A0 (en) 1999-09-22
JP2000512137A (ja) 2000-09-19
BR9709529A (pt) 1999-08-10
AU3337297A (en) 1998-01-05
WO1997046585A2 (fr) 1997-12-11
CZ397898A3 (cs) 1999-04-14
NZ332879A (en) 2000-09-29
NO985683D0 (no) 1998-12-04
CN1221426A (zh) 1999-06-30
NO985683L (no) 1998-12-04
WO1997046585A3 (fr) 1998-04-23
CA2257240A1 (fr) 1997-12-11
KR20000016402A (ko) 2000-03-25
TR199802534T2 (xx) 1999-03-22

Similar Documents

Publication Publication Date Title
PL330361A1 (en) Leptin fragments (ob proteins)
AU4922497A (en) Interleukin-18-receptor proteins
AU4467497A (en) Chaperone fragments
AU6721696A (en) Cd44-like protein
ZA9710338B (en) Proteins
GB9614033D0 (en) Modified protein G and fragments thereof
AU1538497A (en) Anti-gp46 antibodies and fragments thereof and their use
AU2541397A (en) Tissue remodeling proteins
AU3640397A (en) Ob protein binding protein
IL122569A0 (en) Anti-obesity proteins
AU4586497A (en) Calcium-integrin binding protein
AU4582597A (en) Therapeutic proteins
AU4505497A (en) Snrnp sm proteins
AU1036397A (en) Chaperone fragments
EP1007648A4 (fr) Proteines anti-obesite
AU2003204475A1 (en) Fragments of leptin (ob protein)
EP0915100A4 (fr) Nouvelle proteine
GB9604865D0 (en) Modified proteins
AU5211899A (en) Chromatin associated proteins
GB9828306D0 (en) Modified protein G and fragments thereof
GB9707599D0 (en) Proteins
GB9607689D0 (en) Proteins
GB9614293D0 (en) Modified proteins
GB9624028D0 (en) Modified proteins
GB9611896D0 (en) Modified proteins